These are links to recent news stories that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Cladribine risk reappraised
Research has shown that the incidence of cancer in people taking cladribine was no greater than in other MS drugs. Development of cladribine as a treatment for relapsing MS was stopped in 2011 but the new research suggests there is no evidence for an increased risk of cancer
Source: Eureka Alert
MS Trust link: Cladribine